Reyataz (Atazanavir Powder for Oral Suspension) and Tekamlo
Determining the interaction of Reyataz (Atazanavir Powder for Oral Suspension) and Tekamlo and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Atazanavir may increase the blood levels and effects of amLODIPine. You may be more likely to experience serious side effects such as irregular heart rhythm, fluid retention, swelling, heart failure, and excessively low blood pressure. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. You should seek medical attention if you develop dizziness or fainting; sudden, unexplained weight gain; swelling of the hands, ankles, or feet; chest pain; or difficulty breathing during treatment with these medications. Avoid driving or operating hazardous machinery until you know how the medications affect you, and use caution when getting up from a sitting or lying position. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration with atazanavir may increase the plasma concentrations and pharmacologic effects of calcium channel blockers, especially the dihydropyridines (e.g., amlodipine, felodipine, nicardipine, nifedipine, nisoldipine). The mechanism involves atazanavir inhibition of intestinal and hepatic CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of most calcium channel blockers. In a pharmacokinetic study, coadministration of atazanavir (400 mg once a day) and diltiazem (180 mg once a day) resulted in a 2-fold increase in diltiazem plasma concentration, and an additive prolonging effect on the PR interval was observed.
MANAGEMENT: Close monitoring of clinical response and tolerance is recommended if calcium channel blockers are used in combination with atazanavir. Dosage reduction may be required for the calcium channel blocker, particularly if it is a dihydropyridine. ECG monitoring may be appropriate due to potential additive effects on the PR interval. Patients should be advised to seek medical attention if they experience edema or swelling of the lower extremities; sudden, unexplained weight gain; difficulty breathing; chest pain or tightness; or hypotension as indicated by dizziness, fainting, or orthostasis.
- "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.
Generic Name: atazanavir
Brand name: Reyataz
Synonyms: Reyataz
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Reyataz (Atazanavir Powder for Oral Suspension)-Tekral Tablets
- Reyataz (Atazanavir Powder for Oral Suspension)-Tekturna
- Reyataz (Atazanavir Powder for Oral Suspension)-Tekturna HCT
- Reyataz (Atazanavir Powder for Oral Suspension)-Telaprevir
- Reyataz (Atazanavir Powder for Oral Suspension)-Telavancin
- Reyataz (Atazanavir Powder for Oral Suspension)-Telavancin Hydrochloride
- Tekamlo-Reyvow
- Tekamlo-Rezira
- Tekamlo-Rh(D) Immune Globulin
- Tekamlo-Rheumatrex
- Tekamlo-Rheumatrex Dose Pack
- Tekamlo-Rheumatrex Dose Pack Oral